Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma

Glenn J. Hanna, Douglas R. Adkins, Paul Zolkind, Ravindra Uppaluri

Research output: Contribution to journalReview articlepeer-review

38 Scopus citations


The clinical benefit of immunotherapy in recurrent, metastatic head and neck squamous cell carcinoma has fueled interest in revisiting neoadjuvant approaches to complement definitive treatment. Neoadjuvant strategies incorporating immune checkpoint inhibitors and other novel immune-based therapies in head and neck cancer are reviewed here, with particular attention paid to the rationale for these approaches from both a clinical and biologic discovery standpoint. The potential benefits of neoadjuvant immunotherapy include reduction of extent of surgery and the intensity of adjuvant therapy by tumor downstaging, reduction of the risk of distant metastatic spread by early introduction of systemic therapy, conversion of unresectable to resectable disease, and early evaluation of biomarkers of tumor response. We await early trial results utilizing these approaches to confirm both safety and initial efficacy in head and neck cancer.

Original languageEnglish
Pages (from-to)65-69
Number of pages5
JournalOral Oncology
StatePublished - Oct 2017


  • Head and neck cancer
  • Immunotherapy
  • Neoadjuvant


Dive into the research topics of 'Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma'. Together they form a unique fingerprint.

Cite this